{"title":"[Unresectable Gastric Cancer Achieving pCR Via Conversion Surgery after Chemotherapy-Implications for Optimizing Individualized Treatment].","authors":"Naoi Sato, Tatsuya Tanaka, Fuka Fujimoto, Haruka Kirihara, Ryo Nakajima, Shigeyuki Kosaka, Shinnosuke Harata, Kaori Watanabe, Kazuyoshi Shiga, Tomoya Shamoto, Hiroyuki Sagawa, Yoichi Matsuo, Shuji Takiguch","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A patient was diagnosed with T4aN+ Stage Ⅲ gastric cancer. After 2 courses of SOX chemotherapy for initially unresectable disease. Additional pathological evaluation revealed tumor PD-L1 (22C3) CPS≥10, HER2 1+, Claudin18 negative status, and MSI negative. Consequently, 2 courses of SOX plus nivolumab were administered. Post-treatment CT revealed resectability, thus leading to robot-assisted distal gastrectomy with D2 lymph node dissection and Billroth-Ⅱ reconstruction was performed. Postoperative pathology showed no residual tumor cells in the primary lesion or lymph nodes, confirming a pCR (ypT0N0). The postoperative course was uneventful and there were no major complications. At 5 months postoperatively, no recurrence was detected and SOX chemotherapy is currently being administered as postoperative adjuvant therapy.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 8","pages":"530-532"},"PeriodicalIF":0.0000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
A patient was diagnosed with T4aN+ Stage Ⅲ gastric cancer. After 2 courses of SOX chemotherapy for initially unresectable disease. Additional pathological evaluation revealed tumor PD-L1 (22C3) CPS≥10, HER2 1+, Claudin18 negative status, and MSI negative. Consequently, 2 courses of SOX plus nivolumab were administered. Post-treatment CT revealed resectability, thus leading to robot-assisted distal gastrectomy with D2 lymph node dissection and Billroth-Ⅱ reconstruction was performed. Postoperative pathology showed no residual tumor cells in the primary lesion or lymph nodes, confirming a pCR (ypT0N0). The postoperative course was uneventful and there were no major complications. At 5 months postoperatively, no recurrence was detected and SOX chemotherapy is currently being administered as postoperative adjuvant therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
